Novartis AGNOVN
▼ ネガティブ資本技術関連度
The failure of a drug from the $12 billion Avidity acquisition pressures CEO Narasimhan and his M&A strategy, wiping ~24 billion Swiss francs off market value.
銘柄への影響 3
Biotech & Genomic Medicine
Novartis AG
Dyne Therapeutics IncDYN
▼ ネガティブ競争関連度
Dyne shares fell 30% as Novartis's del-desiran failure in myotonic dystrophy hit sentiment on rival developers in the same space.
Sarepta Therapeutics IncSRPT
▼ ネガティブ競争関連度
Sarepta shares fell 15.5% amid the read-across from Novartis's failed muscle-wasting drug trial.